Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Sunisa Kongkiatkamon, Anand Tiwari, Vera Adema, PhD, Cassandra M Kerr, MS, Bartlomiej Przychodzen, Hassan Awada, Jibran Durrani, Yvonne Parker, Drew Adams, Yuriy Fedorov, Hetty E. Carraway, MD MBA, Chao-Yie Yang, Mikkael A. Sekeres, MD MS, Daniel J. Lindner, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 881.

https://doi.org/10.1182/blood-2019-128671

Published: 2019

Journal Articles

ASXL1 Mutations Are Associated with Widespread and Distinct DNA Methylation Alterations

Nora E Rahmani, MD, Nandini Ramachandra, Tushar D Bhagat, PhD, Shanisha Gordon, Kith Pradhan, PhD, Bianca Rivera Pena, Mohammad Kazemi, Orsi Giricz, PhD, Shahina Maqbool, Raul Olea, Hamid Dolatshad, Vickram Tittrea, Dharamveer Tatwavedi, Shalini Singh, Andrea Pellagatti, Jacqueline Boultwood, Amit Verma, MBBS

Blood (2019) 134 (Supplement_1): 2989.

https://doi.org/10.1182/blood-2019-126850

Published: 2019

Journal Articles

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Artavazd Arumov, BSc, Piumi Y. Liyanage, BS, Asaad Trabolsi, MD, Lingxiao Li, PhD, Evan R. Roberts, BS, Daniel Bilbao, PhD, Roger M. LeBlanc, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 4061.

https://doi.org/10.1182/blood-2019-122599

Published: 2019

Journal Articles

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

Judith Lind, PhD, Felix Czernilofsky, Sonia Vallet, MD, Fengjuan Fan, PhD, Martin Sattler, PhD, Latifa Bakiri, Erwin F Wagner, PhD, Martin Percherstorfer, MD, Klaus Podar, MD PhD

Blood (2019) 134 (Supplement_1): 4415.

https://doi.org/10.1182/blood-2019-125202

Published: 2019

Journal Articles

Pharmacological Perturbation of the Immunoproteasome in Hematologic Neoplasias: Therapeutic Implications

Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Megan Bariteau, BSc, Minasri L. Borah, Sam Bender, Janaka Foneska, Jennifer Roth, Richard Groen, Gina Walter, Manja Friese-Hamim, Samantha M. Goodstal, Michael Sanderson, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 1291.

https://doi.org/10.1182/blood-2019-130356

Published: 2019

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

DHODH Inhibitors in the Treatment of Acute Myeloid Leukemia: Defining the Mechanism of Action and the Basis of the Metabolic Therapeutic Window

Peggy P. Hsu, MD PhD, Youmna Kfoury, PhD, Najihah Aziz, Jenna Elkhoury, Brittany Hallgren, David T. Scadden, MD, Matthew Vander Heiden, MD PhD, David B Sykes, MD PhD

Blood (2018) 132 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2018-99-113387

Published: 2018

Journal Articles

A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis

Ashwin Kishtagari, MBBS, Kwok Peng Ng, PhD, Charlotte Jarman, Anand D. Tiwari, PhD, James G Phillips, PhD, Caroline Schuerger, Babal K. Jha, Yogenthiran Saunthararajah, MD

Blood (2018) 132 (Supplement 1): 216.

https://doi.org/10.1182/blood-2018-99-119311

Published: 2018

Journal Articles

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Yihong Guan, Anand D. Tiwari, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Yvonne Parker, Cassandra M. Hirsch, Amy C Graham, BS, MS, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, James G Phillips, PhD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4345.

https://doi.org/10.1182/blood-2018-99-117186

Published: 2018

Journal Articles

Computational Identification of Tractable Drug-like Inhibitors of eIF4A1

Derek Essegian, BS, MS, Tyler A. Cunningham, BS, Jonathan H. Schatz, MD, Stephan Schurer, PhD

Blood (2018) 132 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2018-99-116829

Published: 2018

Journal Articles

RNAi and CRISPR/Cas9 Based In Vivo Models for Drug Discovery

Prem Premsrirut, MD PhD, Chia-Lin Wang, PhD, Yu-ting Yang, PhD, Christof Fellmann, PhD, Lukas Dow, PhD, Johannes Zuber, PhD, Scott Lowe, PhD, Marina Pesic, PhD, Katharina Wolter, PhD, Lars Zender, PhD

Blood (2017) 130 (Supplement 1): 5568.

https://doi.org/10.1182/blood.V130.Suppl_1.5568.5568

Published: 2017

Journal Articles

Pharmacologic Inhibition of PI3Kδ Prolongs Survival of Mutant Shp2 E76K -Expressing Mice

Lisa Deng, Elizabeth L Virts, PhD, Rebecca J Chan, MD PhD

Blood (2017) 130 (Supplement 1): 1240.

https://doi.org/10.1182/blood.V130.Suppl_1.1240.1240

Published: 2017

Journal Articles

HUWE1 Inhibition As a Therapeutic Strategy to Target MYC in MM

Lisa J Crawford, BSc, PhD, Dharminder Chauhan, PhD, Alexandra E Irvine, PhD FRCPath

Blood (2017) 130 (Supplement 1): 3077.

https://doi.org/10.1182/blood.V130.Suppl_1.3077.3077

Published: 2017

Journal Articles

Enhancing the Efficacy of CAR T Cells

Crystal L. Mackall, MD

Blood (2017) 130 (Supplement 1): SCI-15.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-15.SCI-15

Published: 2017

Journal Articles

RSK Inhibition Suppresses AML Proliferation through Activation of DNA Damage Pathways and S Phase Arrest

Ritika Dutta, BS, Maria Castellanos, MD, Bruce Tiu, Hee-Don Chae, PhD, Kara L. Davis, DO, Kathleen M. Sakamoto, MD PhD

Blood (2016) 128 (22): 2894.

https://doi.org/10.1182/blood.V128.22.2894.2894

Published: 2016

Journal Articles

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Xiaorong Gu, PhD, Reda Z. Mahfouz, MD, PhD, Quteba Ebrahem, Francis Enane, Tomas Radivoyevitch, PhD, Michael J. Clemente, M.S., Bartlomiej P Przychodzen, MSc, Zhenbo Hu, MD PhD, Ramesh Balusu, PhD, Claudiu V. Cotta, MD, David N. Wald, MDPhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, Jaroslaw P Maciejewski, MD PhD FACP, Yogenthiran Saunthararajah, MD

Blood (2016) 128 (22): 444.

https://doi.org/10.1182/blood.V128.22.444.444

Published: 2016

Journal Articles

A Chemical Modifier Screen in Zebrafish Mutants for the Spliceosomal Component Sf3b1reveals Genotype-Selective Vulnerabilities

Rosannah C. Cameron, PhD, Mia McKinstry, Adriana De La Garza, Sara Nik, Peter G Smith, PhD, Silvia Buonamici, PhD, Robert K. Bradley, PhD, Teresa V. Bowman, PhD

Blood (2016) 128 (22): 965.

https://doi.org/10.1182/blood.V128.22.965.965

Published: 2016

Journal Articles

RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

Leslie A Crews, PhD, Larissa Balaian, PhD, Heather Leu, BS, Nathaniel Delos Santos, Angela C Court, Anil Sadarangani, PhD, Maria A. Zipeto, PhD, James J La Clair, Reymundo Villa, Sheldon Morris, MD, Rainer F. Storb, MD, Anna Kulidjian, MD, Edward D. Ball, MD, Michael D Burkart, PhD, Catriona Jamieson, MD PhD

Blood (2015) 126 (23): 567.

https://doi.org/10.1182/blood.V126.23.567.567

Published: 2015

Journal Articles

Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience

Ekaterina Bulycheva, MD, Jiri Mayer, Prof., MD, William Hermann Krüger, MD PhD, Peter Dreger, MD, Anna Mies, Zuzana Sustkova, MD, Zdenek Racil, MD, Jirina Prochazkova, MD, Eva Walter, MD, Carsten Hirt, Mark Ringhoffer, MD, Wolfgang E Berdel, MD, Hubert Serve, MD, Christoph Rollig, Katja Sockel, MD, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Christian Thiede, MD PhD, Uwe Platzbecker, MD

Blood (2015) 126 (23): 3817.

https://doi.org/10.1182/blood.V126.23.3817.3817

Published: 2015

Journal Articles

Patients Prescribed Warfarin with Poor Time in Therapeutic Range (TTR) Have Different Beliefs about Their Illness and Anticoagulation Therapy Compared to Those with a Good TTR - Early Results from the Switching Study

John K Abdou, MPharm, Jignesh P Patel, PhD, Bipin Vadher, MD, Alison Brown, BPharm, Lara N Roberts, MD, Raj K Patel, MD, Roopen Arya, PhD, Vivian Auyeung, PhD

Blood (2015) 126 (23): 2331.

https://doi.org/10.1182/blood.V126.23.2331.2331

Published: 2015

NARROW

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

ASXL1 Mutations Are Associated with Widespread and Distinct DNA Methylation Alterations

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

Pharmacological Perturbation of the Immunoproteasome in Hematologic Neoplasias: Therapeutic Implications

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

DHODH Inhibitors in the Treatment of Acute Myeloid Leukemia: Defining the Mechanism of Action and the Basis of the Metabolic Therapeutic Window

A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Computational Identification of Tractable Drug-like Inhibitors of eIF4A1

RNAi and CRISPR/Cas9 Based In Vivo Models for Drug Discovery

Pharmacologic Inhibition of PI3Kδ Prolongs Survival of Mutant Shp2 E76K -Expressing Mice

HUWE1 Inhibition As a Therapeutic Strategy to Target MYC in MM

Enhancing the Efficacy of CAR T Cells

RSK Inhibition Suppresses AML Proliferation through Activation of DNA Damage Pathways and S Phase Arrest

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

A Chemical Modifier Screen in Zebrafish Mutants for the Spliceosomal Component Sf3b1reveals Genotype-Selective Vulnerabilities

RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience

Patients Prescribed Warfarin with Poor Time in Therapeutic Range (TTR) Have Different Beliefs about Their Illness and Anticoagulation Therapy Compared to Those with a Good TTR - Early Results from the Switching Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only